Trial · NCT03632772
Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
NCT03632772, Phase 2, Unknown, Buddhist Tzu Chi General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP. Trials, record NCT03632772. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03632772
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
- NCT number
- NCT03632772
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 130 participants, estimated
- Lead sponsor
- Buddhist Tzu Chi General Hospital
- Conditions
- Overactive Bladder Syndrome
- Interventions
- Solifenacin 5Mg, Mirabegron 50 MG
- First posted
- 2018-08-15
- Last updated
- 2018-08-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Urgency Severity Scale (USS) | from baseline to 4 weeks | The change of USS from baseline to 4 weeks after catheter removal and starting OAB medication. |
| Secondary | Overactive Bladder Symptom Score (OABSS) | from baseline to 2 weeks and 4 weeks. | The changes of OABSS |
| Secondary | frequency episodes, urgency episodes, urgency urinary incontinence (UUI) episodes in the 3-day voiding diary | from baseline to 2 weeks and 4 weeks. | The changes of frequency episodes, urgency episodes, urgency urinary incontinence (UUI) episodes in the 3-day voiding diary |
| Secondary | maximum flow rate (Qmax) | from baseline to 2 weeks and 4 weeks. | The changes of maximum flow rate (Qmax) |
| Secondary | voided volume (Vol) | from baseline to 2 weeks and 4 weeks. | The changes of voided volume (Vol) |
| Secondary | Postvoid residual volume (PVR) | from baseline to 2 weeks and 4 weeks. | The changes of Postvoid residual volume (PVR) |
| Secondary | International Prostate Symptom Score (IPSS) | from baseline to 2 weeks and 4 weeks. | The changes of International Prostate Symptom Score (IPSS) |
| Secondary | quality of life index (QoL-I) | from baseline to 2 weeks and 4 weeks. | The changes of quality of life index (QoL-I) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03632772
GET https://conductscience.org/api/trials/v1/NCT03632772/registered